| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 16,039 | 16,006 | ||
| General and administrative | 128,319 | 132,848 | ||
| Total operating expenses | 144,358 | 148,854 | ||
| Loss from operations | -144,358 | -148,854 | ||
| Other income | 0 | 0 | ||
| Interest income | 1 | 1 | ||
| Interest expense on loan payable | 2,521 | 2,493 | ||
| Non-cash interest expense on convertible notes | 18,483 | 18,282 | ||
| Accretion to redemption value on convertible notes | 0 | 0 | ||
| Total other income (expense), net | -21,003 | -20,774 | ||
| Loss before provision for income taxes | -165,361 | -169,628 | ||
| Provision for income taxes | 0 | 2,400 | ||
| Net loss | -165,361 | -172,028 | ||
| Basic loss per common share | -0.02 | -0.02 | ||
| Diluted loss per common share | -0.02 | -0.02 | ||
| Weighted average number of common shares outstanding - basic | 7,236,447 | 7,236,447 | ||
| Weighted average number of common shares outstanding - diluted | 7,236,447 | 7,236,447 | ||
Mosaic ImmunoEngineering Inc. (CPMV)
Mosaic ImmunoEngineering Inc. (CPMV)